ATG Plus PTCy vs ATG for CGVHD Prophylaxis
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
Acute Leukemia|Myelodysplasia|Chronic Graft-versus-host-disease
DRUG: Cyclophosphamide|DRUG: Anti-Thymocyte globulin (rabbit)
Registration of 80 patients within twenty four months, Registration will be documented by the Clinical Research Organization (Ozmosis Research Inc.), 24 months
CRFS, Chronic graft versus host disease free- and relapse-free survival (CRFS), 27 months|GRFS, Graft versus host disease-, and relapse-, free survival (GRFS), 27 months|Survival, Survival (dead/alive) at 100 days for each patient, 27 months|Complete data collection, The Clinical Research Organization (Ozmosis Research Inc.) will document completeness of data collection, 27 months|Cost of study, The sponsor (McMaster University) and the Clinical Research Organization (Ozmosis Research Inc.) will compare actual total trial costs in Canadian dollars at trial completion (at completion of outcomes analysis and report) with expected costs as determined for the trial budget., 27 months
Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.